2024 | BioSenic

New transparency notifications

Read more about New transparency notifications

Mont-Saint-Guibert, Belgium, January 3, 2025, 17:30 – BIOSENIC (Euronext Brussels and Paris: BIOS) announces that it has received three transparency notifications from ABO Infinium Americas OpCo LTD.

The details of the notifications are set out below and the full text can be consulted on the website of BioSenic, under the heading “Major shareholders & transparency notices”.

Medsenic, filiale de BioSenic, signe une lettre d'intention conditionnelle qui pourrait sécuriser la prise en charge d'une partie des frais de son essai clinique sur la maladie chronique du greffon contre l'hôte

Read more about Medsenic, filiale de BioSenic, signe une lettre d'intention conditionnelle qui pourrait sécuriser la prise en charge d'une partie des frais de son essai clinique sur la maladie chronique du greffon contre l'hôte

Mont-Saint-Guibert, Belgique, le 13 décembre 2024, 17h30 – BIOSENIC (Euronext Bruxelles et Paris : BIOS) annonce la signature d'une lettre d’intention conditionnelle entre Medsenic SAS et la société basée à Singapour TrialCap Pte. Ltd. constituant une première étape pour une proposition de financement par emprunt et par souscription d'actions.

Medsenic, a subsidiary of BioSenic, has signed a conditional letter of intent that could secure funding to cover part of the costs for its clinical trial on chronic graft-versus-host disease

Read more about Medsenic, a subsidiary of BioSenic, has signed a conditional letter of intent that could secure funding to cover part of the costs for its clinical trial on chronic graft-versus-host disease

Mont-Saint-Guibert, Belgium, 13 December 2024, 17:30 CET – BIOSENIC (Euronext Brussels and Paris : BIOS) announces the signing of a conditional letter of intent between Medsenic SAS and the Singapore based TrialCap Pte. Ltd. as a first step for a proposed financing arrangement through both debt and equity subscription.

Medsenic, a subsidiary of BioSenic, has signed a conditional letter of intent that could secure funding to cover part of the costs for its clinical trial on chronic graft-versus-host disease

Read more about Medsenic, a subsidiary of BioSenic, has signed a conditional letter of intent that could secure funding to cover part of the costs for its clinical trial on chronic graft-versus-host disease

key European patent approval from the EPO for the use of ATO (arsenic trioxide) in treating multiple sclerosis

Read more about key European patent approval from the EPO for the use of ATO (arsenic trioxide) in treating multiple sclerosis

Mont-Saint-Guibert, Belgium, November 27, 2024, 6:00 PM CEST – BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in severe autoimmune and inflammatory diseases, announces that its subsidiary Medsenic has secured a new patent (B180218EP), which will be published on December 25, 2024, on the European Patent Office (EPO) website. The European patent application No. 18722530.5, filed on May 4, 2018, pertains to a “Method for treating multiple sclerosis using arsenic.”

Information on the total number of voting rights and shares

Read more about Information on the total number of voting rights and shares

BioSenic provides third quarter 2024 Business Update

Read more about BioSenic provides third quarter 2024 Business Update

Carole Nicco se retire de ses fonctions de Directrice Scientifique et des Opérations de BioSenic afin de se focaliser sur la filiale Medsenic SAS

Read more about Carole Nicco se retire de ses fonctions de Directrice Scientifique et des Opérations de BioSenic afin de se focaliser sur la filiale Medsenic SAS

Carole Nicco steps down from her roles as Chief Scientific and Operations Officer of BioSenic to focus on the subsidiary Medsenic SAS

Read more about Carole Nicco steps down from her roles as Chief Scientific and Operations Officer of BioSenic to focus on the subsidiary Medsenic SAS

ABO

Read more about ABO